Log in

LON:AVO - Advanced Oncotherapy Share Price, Forecast & News

GBX 39
+1.00 (+2.63 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
37.65
Now: GBX 39
39
50-Day Range
37
MA: GBX 38.71
40
52-Week Range
32.50
Now: GBX 39
52
Volume32,355 shs
Average Volume79,755 shs
Market Capitalization£95.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. Read More…

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-36178728

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 1.82 per share
Book ValueGBX 20 per share

Profitability

Miscellaneous

Employees93
Market Cap£95.10 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter.


Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

What price target have analysts set for AVO?

1 brokers have issued 12 month price objectives for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they expect Advanced Oncotherapy's stock price to reach GBX 155 in the next twelve months. This suggests a possible upside of 297.4% from the stock's current price. View Analyst Price Targets for Advanced Oncotherapy.

What is the consensus analysts' recommendation for Advanced Oncotherapy?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Advanced Oncotherapy.

Has Advanced Oncotherapy been receiving favorable news coverage?

Media coverage about AVO stock has been trending extremely negative on Saturday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advanced Oncotherapy earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Advanced Oncotherapy.

Who are some of Advanced Oncotherapy's key competitors?

What other stocks do shareholders of Advanced Oncotherapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), Lancashire (LRE), Sirius Minerals (SXX), Oxford BioMedica (OXB), Renishaw (RSW), GW Pharmaceuticals PLC- (GWPH), Scancell (SCLP) and Bahamas Petroleum (BPC).

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the folowing people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 76)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Mr. Ed Lee, COO & Sr. VP of Operations
  • Mr. Graham Pughe, Sr. Vice-Pres, Accounting & IT
  • Ms. Geraldine Poindron, Corp. Fin. Mang.

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 39.

How big of a company is Advanced Oncotherapy?

Advanced Oncotherapy has a market capitalization of £95.10 million. Advanced Oncotherapy employs 93 workers across the globe.View Additional Information About Advanced Oncotherapy.

What is Advanced Oncotherapy's official website?

The official website for Advanced Oncotherapy is http://www.advancedoncotherapy.com/.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.


MarketBeat Community Rating for Advanced Oncotherapy (LON AVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel